Sarepta Therapeutics, Inc. drugs
3 results
Amondys 45 (casimersen)
(casimersen)Sarepta Therapeutics, Inc.
Usage: AMONDYS 45 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene suitable for exon 45 skipping. Approval is based on increased dystrophin production in skeletal muscle, with continued approval dependent on clinical benefit verification in further trials.
Exondys 51 (eteplirsen)
(eteplirsen)Sarepta Therapeutics, Inc.
Usage: EXONDYS 51 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a specific DMD gene mutation suitable for exon 51 skipping. Approval is based on increased dystrophin levels in skeletal muscle, with continued use pending further evidence of clinical benefit.
Vyondys 53 (golodirsen)
(golodirsen)Sarepta Therapeutics, Inc.
Usage: VYONDYS 53 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene suitable for exon 53 skipping. Approval is based on increased dystrophin production observed in treated patients, pending further confirmation of clinical benefit.